Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FSAH2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,759
Award facts
- Contract value 100% obligated
- $17,759.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,759.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. The delivery order, issued on December 2, 2025, with an ultimate completion date of December 23, 2025, utilizes firm fixed-price pricing with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 contract awarded on November 13, 2025, that positions the company as a critical pharmaceutical supplier for Department of Defense medical supply needs through December 31, 2036.
DMS Pharmaceutical Group has established itself as a reliable supplier within the federal pharmaceutical supply chain, with demonstrated substantial contracting activity across multiple therapeutic categories including oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's capacity to compete effectively in unrestricted federal procurement, combined with its established performance on numerous delivery orders issued by DLA's Medical Supply Chain division, underscores its capability to fulfill the diverse pharmaceutical requirements of military healthcare facilities. As a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group serves as one of multiple designated suppliers supporting recurring medical supply needs of the Department of Defense globally.
Quick answers
Who was awarded contract SPE2DR26FSAH2?
SPE2DR26FSAH2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DR26FSAH2 worth?
The government has obligated $17,759 on SPE2DR26FSAH2.
Is contract SPE2DR26FSAH2 an order under another contract?
Yes. SPE2DR26FSAH2 is a delivery order under SPE2DR25D9332, an indefinite delivery contract.
Was contract SPE2DR26FSAH2 competed?
The extent of competition for SPE2DR26FSAH2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award